Alzemon: a prospective follow-up study of eslicarbazepine acetate monotherapy in patients with newly diagnosed epilepsy

CONCLUSION: Eslicarbazepine monotherapy in patients with newly diagnosed partial epilepsy, both in the general population and in the population over 65 years old, is effective and safe in routine clinical practice.PMID:33851715 | DOI:10.33588/rn.7208.2020593

Source: Revista de Neurologia - April 14, 2021 Category: Neurology Authors: L Hern ández-Rubio M Asensio-Asensio D Tortosa-Conesa A Alfaro-S áez A Garc ía-Escrivá M D íaz-Román J Montoya M A M éndez-Miralles V Bertol-Alegre M D Castro-Vilanova M L Galiano M E Blanco-Cant ó F L ópez-González Source Type: research